Folliculotropic mycosis fungoides responding to bexarotene gel.

Abstract

Folliculotropic mycosis fungoides (FMF) is an uncommon and potentially aggressive form of cutaneous T cell lymphoma (CTCL). Phototherapy, radiotherapy, and systemic chemotherapy are the most commonly employed treatment options, but may have limited success and common adverse reactions. Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FME The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.

Cite this paper

@article{Walling2008FolliculotropicMF, title={Folliculotropic mycosis fungoides responding to bexarotene gel.}, author={Hobart W. Walling and Brian L. Swick and Pedram Gerami and Richard K Scupham}, journal={Journal of drugs in dermatology : JDD}, year={2008}, volume={7 2}, pages={169-71} }